Right now, there are two FDA approved drugs to treat Alzheimer’s itself. Find out why Remternetug may soon get approval as a third, even better treatment.
Kisunla, the newest Alzheimer’s drug, is rapidly gaining acceptance around the world. Learn what it does and how to get it.
How do the new drugs Leqembi and Kisunla fight Alzheimer’s? Surprisingly, increases in amyloid-beta protein levels can explain the slowing of Alzheimer’s at least as well as the reduction in amyloid plaques.
Dr. Jason Karlawish from Penn Memory Center discusses the careful process of determining if Lecanemab is right for a patient with Alzheimer’s.
Ely Lilly unveils new $1,000,000,000 facility for drugs including Kisunla for Alzheimer’s. New investment will enhance global medicine production, benefiting millions of patients worldwide
In a new Alzheimer’s study, Rexulti (brexpiprazole) significantly reduced agitation. Learn the kinds of agitation it reduced and by how much.
There are no approved treatments for DLB, though it is the second most common type of dementia. Do drugs like donepezil hold the key?
While the initial headlines might seem discouraging, there’s always more to the story. 🌟
The newest Alzheimer’s drugs, Kisunla and Leqembi, are the first to actually slow down Alzheimer’s. How do they compare to each other?
VIDEO + ARTICLE: Kisunla (generic name: Donanemab) slowed cognitive and functional decline 35%. Once-monthly infusions reduced Alzheimer’s plaque 84%.
New research explains how to recognize “Rapidly Progressive Dementia”, why it often involves Alzheimer’s, and what faster change means for daily care and planning.
A beautiful song on living with Alzheimer’s. (Includes lyrics.) Enjoy.
Kindness can become its own motive.We are made kind by being kind. (Eric Hoffer)
It is one of the most beautiful Compensations of this life thatNo man can sincerely try to help anotherWithout helping himself.
What are the early symptoms of Alzheimer’s? When to get a professional evaluation.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
No spam, only news and updates.
